(FHLC) Fidelity MSCI Health Care - Ratings and Ratios
Pharmaceuticals, Biotechnology, Medical Devices, Healthcare Services
Dividends
| Dividend Yield | 1.54% |
| Yield on Cost 5y | 1.84% |
| Yield CAGR 5y | 6.77% |
| Payout Consistency | 90.6% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 12.8% |
| Value at Risk 5%th | 21.1% |
| Relative Tail Risk | 0.32% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.57 |
| Alpha | 2.31 |
| CAGR/Max DD | 0.42 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.355 |
| Beta | 0.526 |
| Beta Downside | 0.526 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.87% |
| Mean DD | 4.87% |
| Median DD | 3.66% |
Description: FHLC Fidelity MSCI Health Care January 14, 2026
The Fidelity® MSCI Health Care Index ETF (FHLC) tracks the MSCI USA IMI Health Care 25/50 Index, allocating at least 80 % of its assets to the index’s constituents, though it may not hold every security. As a non-diversified, U.S.-focused health-care ETF, FHLC offers investors direct exposure to large, mid- and small-cap companies that operate across pharmaceuticals, biotechnology, medical devices, and health-care services.
Key metrics (as of the most recent filing) include an expense ratio of 0.09 %, a dividend yield around 1.2 %, and total assets under management of roughly $5 billion. The fund’s top holdings typically feature industry leaders such as UnitedHealth Group, Johnson & Johnson, and Pfizer, which together account for about 30 % of assets. Sector performance is strongly driven by demographic aging (U.S. population over 65 projected to reach 22 % by 2035), ongoing Medicare policy reforms, and the pipeline intensity of biotech R&D, which together underpin revenue growth rates of 5-7 % annually for the broader health-care market.
For a deeper, data-rich analysis of FHLC’s risk-adjusted returns and how its exposure aligns with macro-level health-care trends, you may find ValueRay’s toolkit useful.
What is the price of FHLC shares?
Over the past week, the price has changed by -0.98%, over one month by +1.57%, over three months by +7.64% and over the past year by +11.94%.
Is FHLC a buy, sell or hold?
What are the forecasts/targets for the FHLC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 79.8 | 6.7% |
FHLC Fundamental Data Overview January 14, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 2.89b USD (2.89b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 2.89b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 2.89b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.85% (E(2.89b)/V(2.89b) * Re(7.85%) + (debt-free company))
Discount Rate = 7.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for FHLC ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle